Evidence map›Paper›PMID 29300680›Full record

ArticleHuman vaccines & immunotherapeutics2018

Utilization pattern of Haemophilus influenza type b vaccine in eight provinces of China.

Yan Li, Chenyan Yue, Yamin Wang, Xu Zhu, Kathryn Martin, Robert W Scherpbier, Jiechen Liu, Zhiguo Wang, Yujie Ma, Huijian Cheng and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Yan Lia National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.
Chenyan Yuea National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.
Yamin Wanga National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.
Xu Zhub China Office of United Nations Children's Fund , Beijing , China.
Kathryn Martinb China Office of United Nations Children's Fund , Beijing , China.
Robert W Scherpbierb China Office of United Nations Children's Fund , Beijing , China.
Jiechen Liuc Immunization Program Department , Shanghai Municipal Center for Disease Control and Prevention , Shanghai , China.
Zhiguo Wangd Immunization Program Department , Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , Jiangsu , China.
Yujie Mae Immunization Program Department , Heilongjiang Provincial Center for Disease Control and Prevention , Haerbin , Heilongjiang , China.
Huijian Chengf Immunization Program Department , Jiangxi Provincial Center for Disease Control and Prevention , Nanchang , Jiangxi , China.
Zhenguo Zhangg Immunization Program Department , Hebei Provincial Center for Disease Control and Prevention , Shijiazhuang , Hebei , China.
Qing Wangh Immunization Program Department , Chongqing Municipal Center for Disease Control and Prevention , Chongqing , China.
Hui Lii Immunization Program Department , Gansu Provincial Center for Disease Control and Prevention , Lanzhou , Gansu , China.
Shen Xiej Immunization Program Department , Guangdong Provincial Center for Disease Control and Prevention , Guangzhou , Guangdong , China.
Qiyou Xiaoa National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.
Huaqing Wanga National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.
Zhijie Ana National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing , China.ORCID 0000-0002-1552-6684
Chinese Center For Disease Control and Prevention · CNGansu Provincial Center for Disease Control and Prevention · CNGuangdong Provincial Center for Disease Control and Prevention · CNHebei Provincial Center for Disease Control and Prevention · CNHeilongjiang Center for Tuberculosis Control and Prevention · CNJiangsu Provincial Center for Disease Control and Prevention · CNNanchang Center for Disease Control and Prevention · CNShanghai Municipal Center For Disease Control Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn China, Hib vaccine is a private-sector vaccine that is an option for parents to select to give to their children; it must be paid for out-of-pocket because it is not included in the government's Expanded Program on Immunization (EPI). We evaluated utilization patterns of Hib vaccine to provide evidence in support of development of a national Hib vaccination strategy.

methodsWe obtained lists of children from immunization information systems (IIS) of counties or districts in 8 provinces of China. Using these lists, we selected 10 children at random from each birth cohort from 2008 through 2012. We obtained Hib vaccination dates from official vaccination certificates. The target sample size was 1,000 children.

resultsWe were able to obtain records for 978 subjects of the selected subjects; of these, 44.79% had received at least 1 dose of Hib vaccine, and 15.54%, 5.83%, 12.27%, and 11.15% had received one, two, three, and four doses, respectively. Per capita GDP was positively correlated with receipt of at least one dose of Hib vaccine. Among the 438 subjects who received Hib vaccine, 27% received 1 dose after 12 months of age; 15%, 7%, and 23% received one of three other patterns of Hib vaccination recommended by the World Health Organization (WHO) [a 3-dose primary series; 2 primary series doses and 1 booster; or 3 primary series doses and 1 booster]. The other 28% of subjects received patterns of Hib vaccination not recommended by WHO. Considering protection from Hib disease as receipt of a WHO-recommended Hib vaccine schedule, 29% of subjects could be considered protected after 12 months of age, 52% could be considered protected during infancy and beyond, and 19% could be considered to not have been protected adequately, despite being vaccinated.

conclusionsCoverage with Hib vaccine was low. There were significant differences between WHO recommendations and actual patterns of use of Hib vaccine, with half of vaccine recipients receiving no protection during infancy and one fifth receiving non-protective Hib vaccination patterns. Inclusion of Hib vaccine into China's EPI system, which provides vaccine at no charge to parents and makes specific vaccination schedule standards, has potential to make more effective use of Hib vaccine.

Indexed as

Bacterial CapsulesChildChinaCross-Sectional StudiesFemaleHaemophilus InfectionsHaemophilus influenzae type bHaemophilus VaccinesHumansImmunization ProgramsImmunization ScheduleImmunization, SecondaryInfluenza, HumanMaleVaccinationVaccines, ConjugateHaemophilus influenzae type b polysaccharide vaccineHaemophilus VaccinesVaccines, Conjugateconcomitant vaccinationHaemophilus influenzae type B vaccineinterval between dosesvaccination agevaccination rate

Identifiers

PMID29300680
PMCPMC5893207
OpenAlexW2781915552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.